Latest From Biotech Now

BIO Patient and Health Advocacy Summit: Patient-Focused Drug Development

95468934

Panelists in this morning’s opening session outlined strategies for the FDA to better engage the patient community to guide the drug development process. “Patients should be providing input and guidance throughout the entire drug review process,” said Marc Boutin, Executive VP and COO of the National Health Council. Boutin highlighted the improvements made through PDUFA V to open up and enhance the Agency’s interaction and engagement with patients. “Integrating our perspective into how drugs are Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

The “Designer Baby” Patent: Why the Patent System Should Not Regulate Science

family_115x76

23andMe received criticism this week from a few bioethicists in the journal Genetics in Medicine, regarding a patent titled “gamete donor selection based on genetic calculations.”   The ethicists write,  “Selecting children in ways such as those patented by 23andMe is hugely ethically controversial… We believe the patent office made a serious mistake in allowing a patent that includes drop-down menus from which to choose a future child’s traits… At no stage during the examination of the patent application Read More >

Patently BIOtech  |  2 Comments  |  Email This Post
Tags: , ,

Biotech IPO Boom or Bubble? The Opening Plenary at the BIO Investor Forum

David Thomas

With 31 (and counting) life sciences companies having already placed IPOs on the market within the first 8 months of this year and many others lining up for S-1 filings, biotech is buzzing about a revival of the IPO market. Is it a bubble? David Thomas, director of Industry Research and Analysis at BIO took up these questions during the opening plenary lunch of the 12th Annual BIO Investor Forum. What’s his short answer? Not Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Successful Public-Private Partnerships

According to BayBio, biomedical companies that can harness the power of patient groups will get medicines, devices and diagnostics to market faster, cheaper and smarter, helping patients and rewarding investors. Gail Maderis, ‎President & CEO at BayBio, debuted their preliminary whitepaper entitled “Successful Public-Private Partnerships” today at the 2013 BIO Investor Forum. BayBio surveyed nearly 100 biotech and foundation CEOs, vice presidents of research, directors of patient advocacy and others across the United States. Following Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

JOBS Act Deconstructed: Regulation A

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act.  BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage. In a nutshell: The JOBS Act directs the SEC to create a new class of securities modeled after those eligible for the existing exemption under SEC Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,